Study links clot-buster, angioplasty combo with increased death risk

09/7/2005 | USA Today

Many heart attack patients are given a clot-busting drug prior to a planned angioplasty, but the combined treatment could increase a patient's risk of death following the artery-widening procedure, according to a new study. Researchers studying 1,667 patients found that 6% of patients given the clot-busting drug TNKase died within 30 days of their angioplasty, compared with just 3.8% of those who had an angioplasty with no clot-buster.

View Full Article in:

USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC